An observational study in Psoriasis, sponsored by Peking University Third Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-02.
Sponsored by Peking University Third Hospital · Observational
The goal of this investigator-initiated, real-world, observational study is to investigate the impact of weight loss on treatment efficacy in overweight or obese Chinese patients with moderate-to-severe plaque psoriasis.
The main question it aims to answer is:
Does a structured weight loss intervention (including dietary management, exercise, and/or pharmacotherapy) improve the clinical response to psoriasis therapy in this population, as measured by the proportion of patients achieving a Psoriasis Area and Severity Index (PASI) score below 3 at Week 24?
Researchers will compare the Weight Loss Intervention Group (receiving standard psoriasis care plus a personalized weight management program) to the Control Group (receiving standard psoriasis care only) to see if the addition of weight loss strategies leads to superior improvements in psoriasis severity, metabolic parameters, and quality of life.
Participants will:
Receive standardized treatment for their psoriasis based on disease severity.
Be allocated (based on patient preference and clinical judgment) to either the intervention or control group.
In the intervention group, receive and follow a personalized weight management plan, which may include dietary counseling, a tailored exercise regimen, and/or Glucagon-Like Peptide-1（GLP-1） receptor agonist therapy (e.g., Semaglutide, Tirzepatide) if indicated.
Undergo scheduled assessments at baseline, Week 12, and Week 24, including:
Clinical evaluations (PASI, Physician's Global Assessment, body surface area).
Anthropometric measurements (weight, BMI, waist/hip circumference).
Quality of life assessment (Dermatology Life Quality Index).
Safety monitoring for adverse events. To investigate the impact of weight loss on treatment efficacy among overweight/obese Chinese patients with plaque psoriasis.
1,899 studies on the registry are indexed under Psoriasis; 233 are open to participants now.
This study's planned enrollment of 70 is below the median of 200 across 396 observational studies indexed under Psoriasis.
Browse Psoriasis studies →Peking University Third Hospital is the lead sponsor of 735 studies on the registry; 262 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Clinical diagnosis of plaque psoriasis and Body Mass Index (BMI) categorized as overweight or obese.
Exclusion Criteria:
receiving standard psoriasis care plus a personalized weight management program
Combination Product: Weight loss and psoriasis treatment
receiving standard psoriasis care only
Combination Product: psoriasis treatment
In the weight loss group, receive standardized treatment for their psoriasis based on disease severity and follow a personalized weight management plan, which may include dietary counseling, a tailored exercise regimen, and/or GLP-1 receptor agonist therapy (e.g., Semaglutide, Tirzepatide) if indicated.
Receive standardized treatment for their psoriasis based on disease severity.
Proportion of PASI<3 at Week 24
Proportion of patients undergoing weight loss treatment who achieve a Psoriasis Area and Severity Index (PASI) score below 3 at Week 24.
Time frame: Week 24
Proportion of PASI<3 at Week 12
Proportion of patients undergoing weight loss treatment who achieve a PASI score below 3 at Week 12.
Time frame: Week 12
Changes of BMI
Changes from baseline in Body Mass Index (BMI) at Week 12 and Week 24 in patients undergoing weight loss treatment.
Time frame: Week 12 and Week 24
Proportion of PGA 0/1 (Physician's Global Assessment)
Proportion of patients undergoing weight loss treatment who achieve a Physician's Global Assessment (PGA) score of 0 or 1 at Week 12 and Week 24.
Time frame: Week 12 and Week 24
Proportion of DLQI<6
Proportion of patients undergoing weight loss treatment who achieve a Dermatology Life Quality Index (DLQI) score below 6 at Week 12 and Week 24
Time frame: Week 12 and Week 24
No study locations are listed for this record.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University Third Hospital